BioCentury
ARTICLE | Finance

Ebb & Flow

October 30, 2006 8:00 AM UTC

One of the signs of a maturing sector is when the fortunes of one company don't cause either panic or euphoria in the rest of the group. Two examples in Europe last week - one on the downside, one on the upside - reflect the growing sophistication of investors.

Paion (FSE:PA8) crumbled E2.36 (26%) to E6.79 last week after the company suspended a Phase III trial of desmoteplase for stroke because the trial's data monitoring committee wanted to review safety data...